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Abstract
A series of Eudragit RS PO-based hot melt extruded films were evaluated as potential transdermal 
systems, with particular emphasis on the inclusion of hydrophilic excipients to allow water sorption, 
which in turn would allow drug release on application to the skin. More specifically, sucrose, methyl 
cellulose, xanthan gum (Xantural®75), poloxamer (Pluronic®F127), Gelucire 44/14 were added to 
Eudragit RS PO and assessed in terms of physical structure (modulated temperature DSC (MTDSC), 
thermogravimetric analysis (TGA), powder XRD (PXRD), scanning electron microscopy(SEM)) and in 
vitro drug release and permeation properties.  In addition, the effect of prior hydration on drug 
permeation was studied for selected systems. Phase separation was noted for sucrose, 
methylcellulose (high loading), xanthan gum (high loading), poloxamer and Gelucire 44/14 (high 
loading) using both visual observation and MTDSC. PXRD studies indicated drug crystallization within 
the phase separated systems. SEM studies broadly followed the same pattern. Dissolution studies 
indicated that the hydrophilic excipients considerably enhanced the release rate, while Franz diffusion 
cell studies showed a much greater variability in effectiveness, which we ascribe to the paucity of 
water of hydration present which would not allow swellable additives such as xanthan to release the 
drug. However, films containing Gelucire 44/14 emerged as the most satisfactory systems, despite the 
higher additive loaded systems showing drug phase separation. This may be related to emulsification 
rather than swelling on contact with water, as noted for the permeation studies involving pre-
hydration. This strategy therefore presents a promising approach for triggered transdermal drug 
delivery, activated by hydration from the skin itself. 
 
Keywords: 
 
Transdermal, polymeric drug delivery systems, amorphous, solid dispersions, hot melt extrusion, 
hydration, excipients, physicochemical characterization.
  
1. Introduction 
 
Hot melt extrusion (HME) technology presents a range of opportunities to design innovative drug 
delivery systems, including patches within the field of transdermal delivery. HME possesses several 
advantages over traditional solvent casting methods for the preparation of patches, including 
continuous processing and avoidance of residual solvent [1-4]. Similarly, the transdermal route offers 
potential advantages of improved drug pharmacokinetics, elimination of gastrointestinal absorption 
problems and the hepatic first pass effect, reduction of dosing and improved patient compliance [5,6]. 
 
In this study we investigate a new approach whereby we include hydrophilic agents in inert HME films 
which, on hydration, will potentially facilitate drug release. The model drug used was ibuprofen ([2-
(4-isobutyl-phenyl) propionic acid], C13H18O2, molecular weight 206.28). Despite having the most 
favourable safety profile of the non-steroidal anti-inflammatory agents (NSAIDs) [7], ibuprofen may 
nevertheless cause gastrointestinal tract (GIT) problems if administered orally, hence there is 
continued interest in developing a transdermal delivery approach for ibuprofen that can circumvent 
such problems [8-13]. The selection of ibuprofen in this study for processing via HME is also of 
particular interest, particularly in relation to possible improvements in polymer extrudability due to 
the ability of this drug to act as a plasticizer during processing [14-15].  
 
In this work, Eudragit RS PO was used as the base polymer. This material is a glassy copolymer 
synthesized from acrylic acid and methacrylic acid esters with 5% of functional quaternary ammonium 
groups and has been used to prepare numerous dosages forms due to its biocompatibility and 
biological safety [16-17]. It is one of the recognized materials for hot melt extrusion [18] as well as for 
transdermal applications [19-21]. Indeed, the relatively high viscosity of Eudragit RS PO on heating 
while dispersive mixing leading to molecular amorphous dispersion has been previously noted [22-
23].  Therefore, the high concentration and thermodynamic activity of ibuprofen that can be achieved 
in this polymer may enhance its skin permeability. Here, hydrophilic excipients were investigated for 
formulation with Eudragit RS PO to enable creation of moisture-triggered delivery systems that may 
be hydrated by the skin itself. Sucrose, methyl cellulose and xanthan gum were selected due to their 
hydrophilicity and tolerable immunological profiles for skin applications. Pluronic® F127 or poloxamer 
407 and Gelucire 44/14 were also used as amphiphilic excipients that can act as solubilising agents. 
Pluronic® F127 is a non-ionic tri-block copolymer of polyoxyethylene(PEO)-polyoxypropylene(PPO)-
polyoxyethylene (PEO) [24] with an HLB value of 22 [25]; this material is considered to be non-irritant 
and non-sensitising in topical and transdermal applications [26-27]. Gelucire® 44/14, with HLB value 
of 14, is a mixture of monoesters, diesters and triesters of glycerol, and monoesters and diesters of 
polyethylene glycols [28] that belongs to the lauryl polyoxylglycerides (macroglycerides) family. 
Because of its numerous pharmaceutical applications, such as self-emulsification [29], and 
biocompatibility [27,30], this material was investigated as an adjuvant to modulate the drug release 
properties from the transdermal patch systems.  
 
Here we examine the effects of hydrophilic agent inclusion on the physical structure and in vitro drug 
release properties of ibuprofen dispersions in Eudragit RS PO.  More specifically, we explore the 
concept of using a system which is inert on storage but which acts as an occlusive layer when placed 
on the stratum corneum, thereby resulting in water uptake into the film. This water would then alter 
the structure of the film so as to allow drug permeation; such alterations may include plasticization, 
swelling or emulsification. Furthermore, the use of an amorphous solid dispersion of the drug in the 
film may maximise the thermodynamic activity of the drug compared to the crystalline form, in turn 
aiding permeation.  Here, we examine the relationship between composition, structure and release in 
order to evaluate the approach but also as a means of identifying the most promising systems for 
further study and development.   
 
2. Materials and Methods  
 
2.1 Materials 
 
Crystalline ibuprofen was kindly donated by BASF (25 US Quality) and Eudragit RS powder (PO) grade 
by Evonik Röhm Pharma polymers. Other excipients possessing hydrophilic character used include 
sucrose (Sigma-Aldrich), methylcellulose (Colorcon), Xantural®75 (CPkelco), Pluronic® F127 (BASF), 
Gelucire 44/14 (Gattefossé SA, Saint Priest, France).  
 
2.2. Methods 
 
2.2.1 Preparation of hot melt extruded ibuprofen based on Eudragit RS PO 
 
Physical mixtures of the drug and the carrier blend of Eudragit and other hydrophilic excipients were 
prepared by simple mixing in a pestle and mortar. The mixes were fed into a co-rotating twin screw 
extruder (Haake Minilab II Micro Compounder, Thermo Scientific, Germany) equipped with a slit 
(sheet) die (orifice). Determination of the minimum ratio between these components was based on 
30% w/w ibuprofen loading. Each batch size was formulated with total weight of 10 grams. 
Temperatures of 90-100˚C from the feed to the die end were used according to the formulation 
prepared and a screw speed was set at 100 rpm for four  minutes, which was found to be suitable for 
the extrusion of these mixtures. The resultant extruded films were cooled along a customised 
conveyer belt to room temperature. These films were separated into unit doses (patches) of roughly 
equal size (approximately 24 mm3). The films were stored between aluminium sheets, except for the 
ones containing Gelucire 44/14, which were stored between silicone sheets due to their high tack. The 
extrudable mixtures obtained as described above were characterised using techniques of MTDSC, 
PXRD and SEM and compared when appropriate with the equivalent physical mixes. The level of 
tackiness of the films was measured qualitatively for the current purposes by holding these films 
between thumb and index finger; for further developmental studies more quantitative methods such 
as texture analysis are available.  The in vitro drug release experiment (dissolution test) and in vitro 
permeation studies were also carried out for the selected optimised formulations. These experiments 
are detailed in the following sections. 
 
2.2.2 Analytical methods 
 
Modulated temperature DSC (MTDSC) measurements were carried out using TA Instrument DSC 
Q1000, equipped with a refrigerated cooling system (RCS).  Calibration was performed prior to each 
analysis; temperature calibration was performed using indium, benzoic acid and n-octadecane, while 
heat capacity calibration was performed using aluminium oxide. Data were analysed using TA 
Universal Analysis 2000 software and nitrogen was used as the purge gas through the DSC cell at a 
flow rate of 50 ml/min. TA instruments standard pans were used for all calorimetric studies and the 
mass of each empty sample pan was matched to the mass of the empty reference pan within ±0.05 
mg and all measurements were performed in triplicate. For the MTDSC experiments, an amplitude of 
±0.265°C, period of 100 seconds and underlying heating rate of 1°C/min were used. The samples were 
subjected to two steps in this method. The first step was equilibration at -70˚C, isothermal heating for 
5 minutes followed by a second step of heating to 100˚C. The glass transition temperatures (Tgs) were 
in all cases taken at the midpoint of the transitions from the reversing heat flow signals. All 
measurements were performed in triplicate. Thermal stability of the materials was studied using 
thermogravimetric analysis, which was performed using TGA Q5000 IR (TA Instruments, U.K). Samples 
(10.00-12.00 mg) were subjected to a single step of heating from 30°C to 300˚C at a heating rate of 
10˚C min-1. All TGA runs were performed in open aluminium pans with a dry nitrogen gas purged at 
flow rates of 25 ml min-1 and 10 ml min-1 through the furnace and TGA head, respectively. Data were 
treated mathematically using TA Universal Analysis 2000 software to illustrate weight loss percentage 
and weight derivative loss signals. The extrusion temperatures were selected on the basis of their 
being below the decomposition temperature of the component with the lowest thermal stability (see 
Appendix A). The water content in the hydration study was also measured using TGA and samples (~10 
mg) were heated at 10°C/min from 30°C to 250°C. 
 
Qualitative powder X-ray diffraction (PXRD) was used to detect crystalline ibuprofen in the extruded 
samples as compared to the respective physical mixes. Analysis was performed using an X-ray powder 
diffractometer (ARL Xtra, manufactured by Thermo Fisher Scientific) equipped with X-ray tube 
(Copper, wavelength of 1.540562 Angstrom) over the 2Ө range from 2 to 60 degrees, scanning speed 
of 1.2˚/min (step: 0.01 degree, 0.5 sec/step) using a 40 kV generator and a 20 mA stream. 
 
Scanning electron microscopy (SEM) was used to visualise crystalline ibuprofen of the extruded 
samples and thus detecting any sign of phase separation on that basis. For that purpose, 
morphological features of the surface and cross sections of the extruded formulations were examined. 
The samples were mounted onto stubs using double-sided tape and were gold coated, in order to 
increase conductivity of the electron beam, by a Polaron SC7640 sputter gold coater manufactured by 
Quorum Technologies (UK), using Plasma current of 20 mA, Voltage: 2.1 kV for 30 seconds. The 
photographs taken were obtained using scanning electron microscope (JSM 5900LV, manufactured by 
JEOL,Japan) fitted with a tungsten (W) filament, acceleration voltage of 20 kV and 10 mm working 
distance.  
 
2.2.3 In vitro drug release (dissolution) studies 
 
Drug release studies were performed using the paddle and vessel assembly with the addition of a 
stainless steel basket. The design of this hybrid basket-paddle system was adapted from Grundy et al. 
[31], yielding the advantage of high agitation from the paddle apparatus combined with floatation 
prevention using the basket apparatus.  
 
Hot melt extruded films based on Eudragit RS PO, formulated with different hydrophilic excipients at 
30% (w/w) drug loading were cut manually and the dimensions were measured with an electronic 
digital caliper (MS092 Toolzone Vernier Caliper, UK). The films had similar dimensions of 
approximately 6mm x 4mm x 1mm (length, diameter, thickness). In all the experiments under sink 
condition, the dissolution medium consisted of 900 ml phosphate buffer solution (PBS, pH 7.2) was 
maintained at 37.0 ±0.1°C using a dissolution bath (Copley Apparatus, UK), and the stirring rate was 
set at 100 rpm. Samples (5 mL) were withdrawn at specified time intervals, replacing the same volume 
with the fresh dissolution medium. The samples were then filtered using a 0.20 µm filter (Sartorious 
stedim biotech Minisart®) and analyzed using UV spectrophotometer (PerkinElmer, Lambda XLS) at 
λmax determined for ibuprofen (223 nm). 
 
All results of in vitro release and permeation studies were expressed as mean±standard deviation. 
Statistical analysis involved application of ANOVA and t-tests as appropriate. These tests were 
performed using Analysis toolPak software from Microsoft®office 2013. 
 
2.2.4 In vitro permeation (diffusion) studies 
 
In vitro drug permeation testing is an important tool for the characterisation of transdermal systems 
and has been shown, in some cases at least, to provide a good correlation with biological response 
[32]. A Franz Cell diffusion system (PermeGear Inc., Hellertown, PA, USA) composed of six 9-mm 
vertical diffusion cells with identical characteristics were used to measure the release of ibuprofen 
from different formulae through silicone membranes. Jacketed Franz cells were connected to a water 
bath maintained at 37°C. However, the measured temperature in the donor chambers was 
approximately 32±1°C, mimicking normal skin temperature [33]. The receptor chambers were filled 
with 5ml phosphate buffer (pH 7.2). The silicone membranes (Specialty Silicone Products Inc.,USA, 102 
µm thickness) were cut into suitable sizes to cover the diffusion areas of the diffusion cells (0.79 cm2), 
and were placed between donor and receptor chambers. Silicone membranes were selected because 
of their rate limiting characteristics akin to those of skin [34]. These membranes were soaked 
previously in isopropyl myristate (IPM) for 1 hour, as the latter has bipolar properties that tend to 
mimic the biochemical composition of the skin [35-36].  
 
Eudragit RS PO-based hot melt extruded films (approximate dimensions of 6mm x 4mm x 1mm) loaded 
with ibuprofen at 30% w/w loading were tested.The sampling ports and the donor chambers were 
covered with double layers of Parafilm® to minimise evaporation from the openings. The receptor 
solution was maintained in sink conditions with respect to the drug and stirred at a fixed speed of 500 
revolutions per minute. Aliquots of 0.2 ml were taken of the receptor phase, at specified time 
intervals, and evaluated spectrophotometrically at a wavelength of 223 nm. To best characterise the 
permeation properties of ibuprofen in the used experiment design without vehicle influence i.e. 
Eudragit RS PO,  a saturated solution of ibuprofen in PBS medium (pH 7.2) was run in a similar 
procedure to the extruded films using a volume of 0.3 ml to fill the donor chamber.  
 
2.2.5 Hydration study 
 
To probe the influence of hydration on the enhancement of ibuprofen permeation across silicon 
membranes, the release from 10% (w/w) xanthan gum), 10% (w/w) Gelucire 44/14) and 20% (w/w) 
Gelucire 44/14 was assessed under two conditions, namely Test 1 and Test 2.   
 
In Test 1, the extruded films in the Franz-diffusion donor chamber were immersed with 0.3 ml 
(maximum capacity of this chamber) of the phosphate buffer medium (pH=7.2), which is also used in 
the receptor phase; this took place just before testing. The second condition (Test 2) was exposing 
fresh films to a controlled relative humidity of 95% at 25°C using DVS machine (TA Q5000 SA analyzer, 
TA Instruments Ltd., UK). The films were held at this humidity level for 3 hours to achieve near 
equilibrium at this condition prior application to the Franz Cell diffusion system. Samples were placed 
into tared hemi-sphere quartz sample crucibles (180 μL). Analyses were performed using TA Universal 
Analysis 2000 software.  
 
 
3. Results and Discussion 
 
3.1 Impact of hydrophilic excipients on solid-state properties of drug-loaded Eudragit RS PO films 
 
For the majority of the extruded films, transparent systems were produced even at drug loadings of 
30% (w/w) ibuprofen. The amount of hydrophilic excipient added to the parent polymer (Eudragit RS 
PO) was initially selected at two levels for each system, low (6:1:3 Eudragit RS PO: additive: ibuprofen) 
and high (1:6:3 Eudragit RS PO: additive: ibuprofen). The higher loading was only possible for 
methylcellulose and xanthan gum; the second level was not achievable for sucrose, poloxamer and 
Gelucire 44/14 as the extruded material was liquid and could not stream into the outlet (die). Instead, 
a higher excipient level of 5:2:3 Eudragit RS PO: additive: ibuprofen was used with Gelucire 44/14 with 
only the low levels used (6:1:3) for sucrose and poloxamer. Table 1 summarises the systems under 
study based on these initial tests.  
 
The visual examination of the successfully extruded films is described in Table 1, along with the 
reference terms for each formulation. It was noted that the high xanthan gum and methyl cellulose as 
well as the low sucrose systems all showed a cloudy appearance; this may be a reflection of either the 
excipient or the drug. There were also differences in the physical appearance in terms of texture, with 
the methylcellulose showing a rough and cracked appearance.. Extruded films which contained 
Gelucire 44/14 were found to have the highest observed tack, whereas films containing poloxamer, 
sucrose or low level of xanthan gum (FM5) showed medium tack profiles. This is an important feature 
to address, as tack or “stickiness” would facilitate the film adhering to the skin but may also be a 
difficulty associated with large-scale manufacture.  
 
Table 1: Overview of the appearance and tactile properties of Eudragit RS PO-based hot melt 
extruded films loaded with ibuprofen 
 
Carrier system(s)  
With drug loading 
of  
30% w/w 
Carrier 
composition 
(% w/w 
polymer 
:additive) 
Formula 
code 
Extrusion 
temperature 
(°C) 
Translucency Appearance 
Eudragit RS PO 70 
FM0 
(Control) 
 
100 
√ Smooth, no 
cracks, low tack. 
Eudragit RS PO/ 
Sucrose ratio 
60:10 FM1 
 
100 
X Smooth, no 
cracks, medium 
tack. 
Eudragit RS PO/  
Methyl cellulose 
ratios 
60:10 FM3 
100 √ Rough, no cracks, 
low tack. 
10:60 FM4 
100 X Rough, cracked, 
no tack. 
Eudragit RS PO/ 
Xanthan gum ratios 
60:10 FM5 
 
100 
√ Smooth, no 
cracks, medium 
tack. 
10:60 FM6 
 
100 
X Smooth, sporadic 
cracks, low tack. 
Eudragit RS PO/ 
Poloxamer ratio 
60:10 FM7 
 
90 
√ Smooth, no 
cracks, medium 
tack. 
Eudragit RS PO/ 
Gelucire 44/14 
ratios 
60:10 FM9 
 
90 
√ Smooth, no 
cracks, high tack. 
50:20 FM10 
 
90 
√ Smooth, no 
cracks, high tack. 
 
The MTDSC responses of representative samples are shown in Figures 1-3. The reversing heat flow 
signals were used to assign the glass transition temperature (midpoint-Tg), whereas the melting 
endotherm was identified from the total heat flow signals. Dehydration of sorbed water (residual) led 
to broad endothermic peaks in non-reversing signals over an approximate temperature range of 30 to 
90°C exemplified in Figure 2. 
 
From these DSC studies, it was found that extruded formulations of FM0 (Eudragit RS PO and 
ibuprofen), FM3 (low level of methylcellulose), FM5 (low level of xanthan gum) and FM9 (low level of 
Gelucire 44/14) were characterized by single glass transition temperatures drawn from reversing heat 
signals (mean values) around 9.6±0.2°C, -3.5±1.6°C, -6.7 ± 0.9 °C and 1.5±0.7°C, respectively (Figure 
1). This implies a one-phase system (i.e. a molecular dispersion of drug and the carrier blend) at these 
extruded compositions.  
 
 
 
 
 
 
 
 
Figure 1: MTDSC reversing heat flow signals for hot melt extruded films (see Table 1 or text for their 
compositions)  
 
On the other hand, phase separation can be observed in all other extruded formulations as shown in 
Figure 2-3.The addition of sucrose (FM1) or high level of methyl cellulose (FM4) led to melting 
endotherms around  51.2±1.2°C  or 60.8±0.2 (Tm (onset)), respectively. We tentatively interpret these 
peaks as depressed melting point of ibuprofen, implying that the inclusion of these excipients at this 
composition has led to crystallization of the ibuprofen (Tm (onset) 75.7±0.2˚C). Similarly, inclusion of 
high level of Xantural® 75 (xanthan gum) resulted in multiple peaks which indicates a relatively 
complex phase separation profile (Figure 2).  Likewise, the formulation containing an increased level 
of Gelucire 44/14 (FM10; Figure 2) resulted in a glass transition at 21.8±0.4°C. However, a second 
phase was detected with an exotherm having an extrapolated onset temperature around 5.4±1.1°C 
and peak temperature at 17.6±0.2°C, followed by an endothermic melting peak (Tm (onset) 29.3±1.5°C). 
It is not clear whether this peak represents ibuprofen or Gelucire 44/14 although this issue will be 
addressed using PXRD in a subsequent section.  
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           FM6                 FM10 
 
Figure 2: MTDSC heating scan of hot melt extruded ibuprofen for FM1 composition (Sucrose, Eudragit 
RS PO and ibuprofen; 1:6:3), FM4 (high level of Methylcellulose, Eudragit RS PO and ibuprofen; 6:1:3), 
FM6 (high level of Xanthan gum, Eudragit RS PO and ibuprofen; 6:1:3) and FM10 (high level of Gelucire 
44/14, Eudragit RS PO and ibuprofen; 2:5:3) compositions  
 
Phase separation was also evident in the poloxamer (Pluronic® F127) system (FM7) as illustrated in 
Figure 3.  It is believed that Pluronic® F127 is separating rather than the drug, as a melting transition 
was noted with an extrapolated onset temperature at 47.4±2.9°C and peak temperature at 56.2±1.9°C 
which correlated well with the values obtained from the melting of this semi-crystalline polymer 
(Pluronic® F127) in the physical mix of FM7 (extrapolated onset temperature at 49.5±0.8°C and peak 
temperature at 53.5±0.1°C). A mean glass transition temperature at -5.4±1.5°C was also observed.  
 
 
 
 
 
Figure 3: MTDSC heating scan of FM7 hot melt extruded film containing poloxamer Eudragit RS PO 
ibuprofen ratio of (1:6:3)  
 
Powder XRD 
 
X-ray powder diffraction profiles are shown in Figure 4 for three formulations as examples of typical 
responses, with both extrudates and physical mixes shown as well as the profiles of the raw materials.  
Figure 4A and B shows the response of crystalline ibuprofen to facilitate identification of phase 
separation of the drug.  Figure 4A shows the responses of the poloxamer systems (FM7) while Figure 
4B shows the responses of the Gelucire 44/14 (low and high additive content, FM9 and FM10).    
 
Broad halo scattering profiles were obtained for the extruded films of FM0 (Eudragit RS PO and 
ibuprofen), FM3 (low level of methyl cellulose), FM5 (low level of xanthan gum), and FM9 (low level 
of Gelucire 44/14), indicate homogenous amorphous systems in each case (data not shown). However, 
peaks from the halo patterns for extruded films of FM1 (Eudragit RS PO 60% (w/w) and sucrose 10% 
(w/w) as carriers), FM4 (high level of methyl cellulose) and FM6 (high level of xanthan gum), indicating 
the presence of crystalline ibuprofen. These observations were consistent with the previous MTDSC 
results and the visual observations. However, the PXRD pattern of the FM7 extruded sample identified 
both poloxamer and ibuprofen crystals as shown in Figure 4(A).  
 
In Figure 4(B), the higher levels of Gelucire 44/14 in FM10 extruded films showed peaks corresponding 
to ibuprofen crystals but not to Gelucire 44/14 itself. Thus, it could be inferred that the phase 
separation of the FM10 extruded films resulted in drug crystallization rather than the lipid itself, with 
the corresponding melting endotherm observed in the MTDSC profile (Figure 2).  This is a surprising 
result, as one usually associated lipids with being in the crystalline form at temperatures below their 
melting points. 
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Figure 4: X-ray powder diffraction profiles comparing crystalline raw materials with the corresponding 
physical mixtures and their equivalent hot melt extruded films for (A) FM7 composition (poloxamer, 
Eudragit RS PO and ibuprofen), (B) FM9 (low level of Gelucire 44/14, Eudragit RS PO and ibuprofen) 
and FM10 (high level of Gelucire 44/14, Eudragit RS PO and ibuprofen) compositions  
 
Scanning electron microscopy  
 
SEM studies were conducted on the extruded samples with exemplar images given in Figure 5. Some 
degree of phase separation was evident in all tested films except FM0 (ibuprofen and Eudragit RS PO), 
FM5 (low level of xanthan gum) and FM9 (low level of Gelucire 44/14) films. Films comprising higher 
levels of methylcellulose (FM4) or containing sucrose (FM1) showed protruding or lined crystals, both 
on the surface and cross section of these extrudates. Similarly, at higher levels of xanthan gum (FM6) 
and at 10% (w/w) poloxamer (FM7), the resulting extruded films showed crystalline structures, but 
mainly on the surface. Interestingly, the formulation of FM3 films (low levels of methylcellulose) 
showed fine granules which may be related to ibuprofen crystals. Drug recrystallization in these 
samples was undetected using MTDSC or PXRD, suggesting that the small amount of crystalline 
material present may be below detection limits of these methods, which have been reported to be 
approximately 5% [37].  
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Figure 5: SEM morphological features of the surfaces (column A) and cross sections (column B) 
obtained for different fresh extruded films loaded with ibuprofen (see text or Table 1 for their 
compositions) 
 
For the films containing Gelucire 44/14, the surface morphology of the low lipid loaded films (FM9) 
did not indicate phase separation, while needle-shape crystals appeared for the higher lipid content 
(FM10) films (data not shown). It was noted that the SEM imaging process itself did appear to cause 
damage to these lipid-loaded film surfaces, as evidenced by visible macroscopic changes; such effects 
are well known and are a result of the heating effects generated by the use of the electron beam. 
Therefore, SEM is not suitable to detect morphological features of these samples.   
 
 
 
 
To summarise, the purpose of the study thus far is to address two approaches that are potentially 
important for transdermal flux of an agent (drug): (i) the generation of molecular dispersions in 
enhancing effective drug concentration or its activity by developing extruded films; and (ii) the 
influence of using a hydrophilic component to allow hydration on contact with the skin and activate 
and/or improve the drug release. For some compositions, the hot melt extrusion process has resulted 
in the production of transparent films, with a single glass transition temperature (MTDSC analysis), 
the absence of crystalline diffraction peaks of ibuprofen and the absence of crystals as detected using 
SEM, all of which indicate molecular dispersions of the drug in the films.  These outcomes were 
associated with the following compositions; FM0 (Eudragit RS PO as a carrier), FM5 (low level of 
xanthan gum), and FM9 (low level of Gelucire 44/14).  It was therefore concluded that ibuprofen was 
molecularly dissolved in these films at a 30% (w/w) drug concentration. Separation of the drug phase 
as crystallites can be observed in all other formulations, particularly  FM1 (with sucrose), FM4 (high 
level of methylcellulose) and FM6 (high level of xanthan gum) films.   
 
3.2 Comparison of the in vitro release of ibuprofen from hot melt extruded formulations 
 
Hot melt extruded films of ibuprofen in Eudragit RS PO alone (control) and with sucrose, methyl 
cellulose, xanthan gum, poloxamer and Gelucire 44/14 were evaluated for their release behaviour 
using in vitro drug release testing in phosphate buffer (pH 7.2) at 37°C over 24 hours. 
 
As illustrated in Table 2, the films formulated with Eudragit RS PO alone (FM0) showed poor drug 
release. In the case of formulations containing Eudragit RS PO in combination with sucrose (FM1) or 
low level of methyl cellulose (FM3), no statistically significant change in cumulative percent release 
was found (P>0.05). However, hot melt extruded films of FM4 (high level of methylcellulose), FM5-
FM6 (formulated with xanthan gum), FM7 (poloxamer) and FM9-FM10 (formulated with Gelucire 
44/14) demonstrated enhanced release profiles. 
 
Table 2: Ibuprofen extruded formulations, extent of phase separation (number of observed phases) 
and physical appearance along with drug crystalline state and in vitro release in phosphate buffer 
(pH 7.2) at 37°C (see text or Table 1 for their compositions) 
 
Formulation 
Code 
Ibuprofen release at 24 hours  
(w/w %) 
Number of observed 
phases  
Detected crystalline 
ibuprofen 
FM0 21.6±0.2 One X 
FM1 21.8±0.3 Three √ 
FM3 25.5±0.1 One √ 
FM4 99.0±0.2 Two √ 
FM5 82.7±0.1 One X 
FM6 94.4±0.7 Three √ 
FM7 42.9±2.5 Two √ 
FM9 58.2±3.0 One X 
FM10 At 4 hours: 98.1±1.2 Two √ 
 
Based on the enhanced release and as is evident from Table 2, formulations of FM5 films (10% (w/w) 
xanthan gum and 60% (w/w) Eudragit RS PO as carriers) and FM9 films (10% (w/w) Gelucire 44/14 and 
60% (w/w) Eudragit RS PO as carriers) appear to be the most encouraging formulations, as they also 
present a potential for promoting drug permeation through ibuprofen amorphous dispersion. 
However, FM7 films with 10% (w/w) poloxamer and FM10 films with 20% (w/w) Gelucire 44/14 were 
found to be extremely effective for improved and rapid ibuprofen delivery, despite the fact that these 
formulations contain crystalline ibuprofen as predicted from PXRD results. This therefore raises the 
issue of whether molecular dispersion is indeed a prerequisite for effective performance in terms of 
their permeation (flux) properties. 
 
 3.3 In vitro release (permeation) studies of the selected formulations 
 
3.3.1 Permeation evaluation  
 
Permeation evaluation was performed using an in vitro model of Franz diffusion cells fitted with 
silicone membranes. As a benchmark, saturated solutions of ibuprofen in PBS (pH 7.2) were examined 
(data not shown) and the permeation of the total amount of the ibuprofen was almost completed 
after 6 hours with circa 97.8% cumulative percent permeation.  
 
In Figure 6, films based only on Eudragit RS PO (FM0) showed poor ibuprofen permeability due to the 
very low release from the extruded films. However, in contrast to the observed enhanced release 
(dissolution) behaviour, the ibuprofen permeation profile from the FM5 extruded films (10% (w/w) 
xanthan gum and 60 % (w/w) Eudragit RS PO as carriers) was even lower than control films containing 
Eudragit RS PO alone (data not shown here). This can be explained by swelling characteristics of the 
xanthan gum polymer included in these films; this hydrophilic polymer requires a sufficiency of water 
to swell and enhance drug release [38-39], as shown in Figure 7. However, the only available water to 
be absorbed therein was the evaporated water from the receptor medium in the Franz cells, which 
appears not to be enough for this swelling to take place.  
 
For poloxamer loaded films (FM7), the permeation profile was enhanced with circa 26% drug 
permeation after three days in comparison with a total of about 9% drug permeated after the same 
period from the control films (FM0) as seen in Figure 6. The inclusion of Gelucire 44/14 in Eudragit RS 
PO films showed a maximum of circa 22% of the total drug permeated after three days from FM9 films 
which contained the lower Gelucire content (10% w/w). However, a marked increase in the 
permeation was detected using FM10 formulation (higher Gelucire content) as compared to other 
formulations tested here. More specifically, these films showed a permeation of nearly 45% of the 
loaded ibuprofen after four days (Figure 6). However, the drug permeation was still not complete over 
the course of the experiment i.e. five to seven days. This may be related to lack of sufficient hydration 
and will be explored in the following section. 
 
 
Figure 6: Ibuprofen diffusion profiles from hot melt extruded films of  FM0, FM7, FM9 and FM10 
formulations tested approximately at 32°C and permeated across silicone membranes into phosphate 
buffer solution (pH=7.2) at 37°C. Each data point represents the mean±S.D. of no less than three 
measurements 
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Figure 7: Photographs illustrating the swelling changes of the hot melt extruded films of ibuprofen with 
Eudragit RS PO and xanthan gum (FM5) post the dissolution experiment:(I) swelled, and removed from 
Franz cells post testing: (II) no swelling 
 
3.3.2 Evaluation of hydration influence on ibuprofen permeation from hot melt extruded 
formulations in vitro 
 
Hydration corresponds to one of the most effective and safe penetration enhancement techniques to 
breach the skin barrier [40]. To explore how hydration may also affect permeation from optimized 
formulations, two categories of films were selected. Firstly, films whereby the ibuprofen is not 
crystalline in the fresh samples were selected (FM5 (10% (w/w) xanthan gum) and FM9 (10% (w/w) 
Gelucire 44/14)). The second type of film chosen is the one that achieved the maximum permeation 
of the drug, namely, the FM10 (20% (w/w) Gelucire 44/14) films. The relationship between drug 
permeation and hydration level inside the Franz cells was examined.  
 
Figure 8 shows the permeation profiles of untreated (non-hydrated) samples compared to the samples 
hydrated using 0.3 ml of the phosphate buffer (pH=7.2) in ‘Test 1’. It is clear that this pre-hydration 
provoked a significant enhancement in the permeation profiles (P<0.05). The maximum drug 
permeation was 85.4% after 72 hours from FM5 films (xanthan gum), 98.9% after 96 hours from FM9 
films (low level of Gelucire 44/14) and around 94.3% after 5 hours from FM10 films (higher level of 
Gelucire 44/14).  
 
Additionally the samples were conditioned at a controlled level of humidity using the DVS at 
95%RH/25°C for three hours and examined for their in vitro permeation behaviour (Figure 9, Test 2). 
The water content of these samples was measured using TGA and compared to the non-hydrated 
samples as shown in Figure 9. This increase in the water content resulted in a profound change of the 
drug permeation in comparison with non-hydrated samples (control) as depicted in Figure 8. An 
increase in the percent of the drug permeated was noticed but in a slower rate than samples exposed 
to the hydration level in ‘Test 1’ (Figure 10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
 
(B) 
 
(C) 
 
 
Figure 8: Ibuprofen diffusion profiles from hot melt extruded films of (A) FM5 (60% (w/w) Eudragit RS 
PO and 10% (w/w) xanthan gum as carriers), (B) FM9 (60% (w/w) Eudragit RS PO and 10% (w/w) 
Gelucire 44/14 as carriers) and (C) FM10 (50% (w/w) Eudragit RS PO and  20% (w/w) Gelucire 44/14 
as carriers)  tested approximately at 32°C and permeated across silicone membrane into phosphate 
buffer solution (pH=7.2) at 37°C. Control: samples without hydration. Test 1: each sample was placed 
in 0.3 ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Test 2: samples were moistened at 
95%RH/25°C for three hours prior testing in the Franz cells. Each data point represents the mean±S.D. 
of no less than three measurements 
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Figure 9: Summary of the measured percentage water contents of different hot melt extruded films 
(see text for their compositions) determined by TGA on freshly basis immediately after extrusion 
(before treatment) and after incubation at 95%RH/25°C for three hours in the DVS (after treatment) 
 
 
 
Figure 10: The time corresponding to 80% or higher of the average cumulative percentage permeation 
of the ibuprofen (over 96 hours) from hot melt extruded films of Eudragit RS PO-based films containing 
Xanthan gum (FM5 composition), Gelucire 44/14 (FM9 and FM10 compositions) tested approximately 
at 32°C and permeated across silicone membrane into phosphate buffer solution (pH=7.2) at 37°C. Test 
1: each sample was placed in 0.3 ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Test 2: 
samples were moistened at 95%RH/25°C for three hours prior testing in the Franz cells   
 
The samples of FM5(xanthan gum) films had clearly  swelled after being hydrated in Test 1 and Test 2, 
assuming the shape of the diffusion area (circular) of the Franz cells.  Similarly, FM9 films exposed to 
hydration were swelled and jellified adapting the shape of the diffusion area. This could take place as 
a function of the swelling of Gelucire 44/14 in these systems as expected after contact with aqueous 
medium as other Gelucires [41]. With the increase in both hydration level (Test 1) and increased 
amount of hydrophilic component in the FM10 formulation (20% (w/w) Gelucire 44/14) compared to 
FM9, the samples became homogenous liquid-like emulsions. Figure 10 exemplifies the shape 
deformation of different films after permeation experiment or otherwise after being hydrated 
externally under glass slides to illustrate the liquid-like consistency of FM10 films following Test 1.   
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 Figure 11: Representative photographs of shape and consistency changes of  hot melt extruded films 
removed from Franz cells post testing (I,II) and exposed to 0.3 ml PBS (pH=7.2) at 32°C to imitate  Test 
1 condition over three hours and under glass slides (III,IV). (I) FM5 films (10% (w/w) xanthan gum) after 
Test 1 and Test 2. (II) FM9 films after Test 1 and Test 2 or FM10 after Test 2. (III) FM9 films (10% (w/w) 
Gelucire 44/14). (IV) liquid-like emulsion of hydrated FM10 films (20% (w/w) Gelucire 44/14). (V) 
Represnts an example of the shape of these films prior testing 
 
Overall, pre-hydration was essential to achieve improved drug permeation from the studied systems. 
The greatest permeation was noted for the higher hydration conditions (Test 1) applied to the higher 
Gelucire content FM10 films.  This lipid excipient is associated with favourable solubilisation [42-43], 
permeation enhancement [30] and self-emulsifying [27, 44-46], hence while the consistency and 
performance need to be considered in conjunction for any system that can be used in practice, the 
inclusion of this excipient does appear to show particular promise as a means of achieving water-
induced release of the drug from the transdermal film. 
 
4. Conclusions 
 
Hot melt extruded films of ibuprofen (30%(w/w)) were prepared using Eudragit RS PO alone and in 
combination with different hydrophilic additives to develop transdermal systems with suitable drug 
release and permeability triggered by hydration from the skin itself. Changes of the molecular 
distribution of the drug took place with different compositions (carrier excipient type and the ratio 
used), with films composed of Eudragit RS PO, ibuprofen and lower amounts of xanthan gum (FM5) 
or Gelucire 44/14 (FM9) noted as being molecular dispersions. 
These compositions, together with formulations that showed superior release profiles with acceptable 
physical features,  were selected for further study and included FM7 (poloxamer) and FM10 (~20% 
(w/w) Gelucire 44/14) films. Pre-hydration, especially in films containing Gelucire 44/14, was notably 
influential and indicated that water sorption from the skin could potentially act as a trigger for drug 
release for these systems.  Of the candidate systems studied, those containing Gelucire 44/14 were 
considered to be particularly promising as, depending on the level included, the key features of 
molecular dispersion, suitable film characteristics and favourable release performance under 
conditions of low hydration are all achievable.  The study has therefore indicated that it is indeed 
possible to develop systems that may release the incorporated drug triggered by low hydration, as 
may be achieved using an occlusive film system applied to the stratum corneum.   
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Appendix A 
 
Table A.1: Summary of the thermal properties of the raw materials (as received) intended for 
processing via HME, as estimated from the used TGA and MTDSC techniques. *: Tg was measured for 
amorphous sample prepared by quench cooling method.**: corresponds to the onset of the secondary 
endothermic peak while the leading melting endotherm corresponds to the small leading shoulder-like 
endotherm at 32.1±1.4°C (Tm (onset)): see Figure A.1. 
 
Tested 
material  
Estimated 
thermal 
stability 
range (°C) 
Estimated 
melting 
point 
temperature 
(Tm(onset),°C) 
Estimated glass 
transition 
temperature  
(Mid-point 
Tg,°C) 
Ibuprofen <140 75.7±0.2 -43.4±0.2 
Eudragit RS 
PO 
<170 - 53.3±0.5 
Sucrose <187 175.2±1.8 - 
Methyl 
cellulose 
<200 - 103.0±0.1 
Xantural®75 <235 - 37.7±2.6 
Pluronic® 
F127 
<163 54.2±1.2 -63.5±0.7 
Gelucire 
44/14 
<150 39.5±0.8* - 
 
 
 
 
Figure A.1: MTDSC heating scan of Gelucire 44/14 in standard aluminium pans. Underlying scan rate 
of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds 
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